Galderma Standardizes on Medidata Rave for Global Dermatology Trials
Medidata Solutions
today announced that
Galderma
has standardized on the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) platform.
Based in Lausanne, Switzerland with a presence in 65 countries, Galderma operates one of the world’s largest R&D facilities dedicated exclusively to developing treatments for dermatological conditions. These state-of-the-art laboratories, located in Sophia Antipolis, France, are complemented by development centers in Princeton, New Jersey and Tokyo, Japan. With an ongoing need to conduct an expanding number of global clinical trials, Galderma’s data management team conducted an extensive, six-month evaluation of three vendors before selecting Medidata Solutions.
“Medidata’s track record executing global trials across all trial phases, coupled with their professionalism, proactivity and responsiveness, was critical to our rollout of the Rave solution,” said Francis Gon, head of Global Data Management at Galderma. “Medidata’s training and eLearning tools also made it easy for us to take the solution in-house and begin to independently build and execute studies in any phase and in multiple languages.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
